AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24132980 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat equicaloric chocolate milkshake
Number of subjects: 106
Study 24132980 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sugar equicaloric chocolate milkshake
Number of subjects: 106
Study 24132980 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing sugar in low-fat milkshakes
Number of subjects: 106
Study 24132980 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing fat content in low-fat milkshakes
Number of subjects: 106
Study 24132980 — intervention group
Group type: COMPARATOR
Intervention: Tasteless solution
Number of subjects: 106
Study 21147857 — intervention group
Group type: EXPERIMENTAL
Intervention: Playing solitaire during lunch (distraction)
Number of subjects: 44
Study 21147857 — intervention group
Group type: COMPARATOR
Intervention: No distraction during lunch (control)
Number of subjects: 44
Study 18637053 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Exchange (PE)
Number of subjects: 280
Study 18637053 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 280
Study 16549954 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug group (heparin, abciximab, or thrombolytics)
Number of subjects: 108
Study 16549954 — intervention group
Group type: COMPARATOR
Intervention: No-drug group
Number of subjects: 108
Study 16549954 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug group
Number of subjects: 108
Study 16549954 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug group (collagen plug devices vs. suture-mediated devices)
Number of subjects: 108
Study 15040435 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programs
Number of subjects: 30
Study 15040435 — intervention group
Group type: EXPERIMENTAL
Intervention: Support programs (telephone, in person, or both)
Number of subjects: 30
Study 15040435 — intervention group
Group type: COMPARATOR
Intervention: Written materials (pamphlets)
Number of subjects: 30
Study 9820297 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant interferon beta‐1a 22 microg
Number of subjects: 560
Study 9820297 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant interferon beta‐1a 44 microg
Number of subjects: 560
Study 9820297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 560
Study 7711393 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Manual rehabilitation programme
Number of subjects: 34
Study 7711393 — intervention group
Group type: COMPARATOR
Intervention: General advice and information booklets
Number of subjects: 34
Study 2665546 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with vincristine, prednisone, L-asparaginase, and rubidomycin (Group B, n = 118)
Number of subjects: 240
Study 2665546 — intervention group
Group type: COMPARATOR
Intervention: Induction treatment with vincristine, prednisone, and L-asparaginase (Group A, n = 122)
Number of subjects: 240
Study 2665546 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 240
Study 333084 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline 250 mg, 6 times per day for 5 days
Number of subjects: 20
Study 333084 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 6 times per day for 5 days
Number of subjects: 20
Study 31483789 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback training (NFT) group
Number of subjects: 33
Study 31483789 — intervention group
Group type: COMPARATOR
Intervention: Sham feedback (SF) group
Number of subjects: 33
Study 28864319 — intervention group
Group type: EXPERIMENTAL
Intervention: CT group (ultrasound and CT results)
Number of subjects: 50
Study 28864319 — intervention group
Group type: COMPARATOR
Intervention: Control group (transthoracic and transesophageal echocardiography data)
Number of subjects: 50
Study 28864319 — intervention group
Group type: EXPERIMENTAL
Intervention: CT group
Number of subjects: 50
Study 28864319 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 25675557 — intervention group
Group type: EXPERIMENTAL
Intervention: Yin-yang meridians acupuncture with respiratory reinforcing and reducing manipulation
Number of subjects: 100
Study 25675557 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment (control group)
Number of subjects: 100
Study 22471559 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg daily
Number of subjects: 26
Study 22471559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 19846007 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment maneuver (RM)
Number of subjects: 20
Study 19846007 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular therapy only)
Number of subjects: 20
Study 17509028 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron 0.5 mg once daily
Number of subjects: 705
Study 17509028 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron 1 mg once daily
Number of subjects: 705
Study 17509028 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron 1 mg twice daily
Number of subjects: 705
Study 17509028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 705
Study 17509028 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron (all groups)
Number of subjects: 705
Study 17509028 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron 0.5 mg
Number of subjects: 705
Study 14512295 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin with standard dose of cytarabine
Number of subjects: 362
Study 14512295 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin with standard dose of cytarabine
Number of subjects: 362
Study 14512295 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone with standard dose of cytarabine
Number of subjects: 362
Study 14512295 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 362
Study 14512295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362
Study 11673750 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (600 mg daily for 5 days)
Number of subjects: 18
Study 11673750 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco smoking
Number of subjects: 18
Study 11673750 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 18
Study 9826861 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotak DSP lead
Number of subjects: 123
Study 9826861 — intervention group
Group type: COMPARATOR
Intervention: Endotak C lead (Control)
Number of subjects: 123
Study 7584300 — intervention group
Group type: EXPERIMENTAL
Intervention: Experienced children (those who had experienced events 8 months prior)
Number of subjects: 21
Study 7584300 — intervention group
Group type: COMPARATOR
Intervention: Matched naive controls
Number of subjects: 21
Study 2774052 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational Therapy Maternal Role Preparation Program (4 sessions)
Number of subjects: 16
Study 891483 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg glucagon (G)
Number of subjects: 30
Study 891483 — intervention group
Group type: COMPARATOR
Intervention: 50 mg pethidine plus 0.5 mg atropine (PA)
Number of subjects: 30
Study 31511036 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality (IVR) with first-person perspective (1PP) during high-intensity intermittent aerobic exercise (HIE)
Number of subjects: 30
Study 31511036 — intervention group
Group type: COMPARATOR
Intervention: Immersive virtual reality (IVR) with third-person perspective (3PP) during high-intensity intermittent aerobic exercise (HIE)
Number of subjects: 30
Study 28902334 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 111
Study 28902334 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Number of subjects: 111
Study 28902334 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Bevacizumab and Triamcinolone
Number of subjects: 111
Study 25185971 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐IRI (nimotuzumab 400 mg weekly plus irinotecan 150 mg/m2 biweekly)
Number of subjects: 82
Study 25185971 — intervention group
Group type: COMPARATOR
Intervention: IRI (irinotecan 150 mg/m2 biweekly)
Number of subjects: 82
Study 25185971 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐IRI (EGFR 2+/3+)
Number of subjects: 82
Study 25185971 — intervention group
Group type: COMPARATOR
Intervention: IRI (EGFR 2+/3+)
Number of subjects: 82
Study 25185971 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐IRI
Number of subjects: 82
Study 25185971 — intervention group
Group type: COMPARATOR
Intervention: IRI
Number of subjects: 82
Study 23248249 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin (IDA)
Number of subjects: 727
Study 23248249 — intervention group
Group type: COMPARATOR
Intervention: Daunorubicin (DNR)
Number of subjects: 727
Study 21852581 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (ACE inhibitor)
Number of subjects: 331
Study 21852581 — intervention group
Group type: COMPARATOR
Intervention: High serum phosphate levels (highest two quartiles)
Number of subjects: 331
Study 21852581 — intervention group
Group type: COMPARATOR
Intervention: Phosphate as a continuous variable
Number of subjects: 331
Study 19923789 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal plasma fibronectin levels
Number of subjects: 100
Study 19923789 — intervention group
Group type: EXPERIMENTAL
Intervention: AOPP levels in normotensive pregnant women
Number of subjects: 100
Study 19923789 — intervention group
Group type: COMPARATOR
Intervention: AOPP levels in preeclamptic women
Number of subjects: 100
Study 19923789 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC curve analysis for total fibronectin
Number of subjects: 100
Study 16713439 — intervention group
Group type: EXPERIMENTAL
Intervention: voglibose (0.9 mg daily)
Number of subjects: 30
Study 16713439 — intervention group
Group type: COMPARATOR
Intervention: diet alone
Number of subjects: 30
Study 17152785 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term cardiac allograft valves after heart transplant
Number of subjects: 146
Study 17152785 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive/anti-inflammatory therapy
Number of subjects: 146
Study 17152785 — intervention group
Group type: EXPERIMENTAL
Intervention: Valvular regurgitation (grade ≥2)
Number of subjects: 146
Study 17152785 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac function parameters
Number of subjects: 146
Study 17152785 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamber dimensions
Number of subjects: 146
Study 12691925 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical NSAIDs
Number of subjects: 108
Study 12691925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 10325851 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard preformed tube
Number of subjects: 100
Study 10325851 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed preformed tube
Number of subjects: 100
Study 10325851 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiral-wound tracheal tubes (both designs)
Number of subjects: 100
Study 10325851 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharp tipped spiral tube
Number of subjects: 100
Study 10325851 — intervention group
Group type: EXPERIMENTAL
Intervention: Obtuse tipped spiral tube
Number of subjects: 100
Study 10325851 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulations after impaction
Number of subjects: 100
Study 8556998 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.9 mg kg‐1
Number of subjects: 4
Study 8556998 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg‐1
Number of subjects: 4
Study 8556998 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.9 mg kg‐1 after 45 s
Number of subjects: 4
Study 8556998 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg‐1 after 45 s
Number of subjects: 4
Study 8556998 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.9 mg kg‐1 after 60 s
Number of subjects: 4
Study 8556998 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg‐1 after 60 s
Number of subjects: 4
Study 2202853 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (Corgard)
Number of subjects: 361
Study 2202853 — intervention group
Group type: COMPARATOR
Intervention: Anapriline
Number of subjects: 361
Study 2202853 — intervention group
Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 361
Study 2202853 — intervention group
Group type: COMPARATOR
Intervention: Pratsiol
Number of subjects: 361
Study 6104255 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 23
Study 6104255 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 23
Study 6104255 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with propranolol and prazosin
Number of subjects: 23
Study 28945640 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballistic Six upper‐extremity plyometric training in addition to the volleyball training
Number of subjects: 28
Study 28945640 — intervention group
Group type: COMPARATOR
Intervention: Volleyball training only
Number of subjects: 28
Study 28742684 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular Aneurysm Repair (EVAR)
Number of subjects: 404
Study 28742684 — intervention group
Group type: COMPARATOR
Intervention: No-intervention
Number of subjects: 404
Study 25752357 — intervention group
Group type: COMPARATOR
Intervention: 10-day hybrid regimen (PACT-10): pantoprazole 40 mg, amoxicillin 1 g, both twice daily for 10 days; plus clarithromycin 500 mg and tinidazole 500 mg, both twice daily for the last 5 days
Number of subjects: 270
Study 25752357 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day hybrid regimen (PACT-14): pantoprazole 40 mg, amoxicillin 1 g, both twice daily for 14 days; plus clarithromycin 500 mg and tinidazole 500 mg, both twice daily for the last 7 days
Number of subjects: 270
Study 23298898 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oral misoprostol and double‐balloon catheter
Number of subjects: 122
Study 23298898 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol alone
Number of subjects: 122
Study 21310539 — intervention group
Group type: EXPERIMENTAL
Intervention: LETS ACT
Number of subjects: 58
Study 21310539 — intervention group
Group type: COMPARATOR
Intervention: Supportive Counseling (SC)
Number of subjects: 58
Study 19370714 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff education and training programme (8 weeks)
Number of subjects: 306
Study 19370714 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 306
Study 17868728 — intervention group
Group type: EXPERIMENTAL
Intervention: Neovastat (shark cartilage extract AE 941)
Number of subjects: 300
Study 15173148 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated bednets
Number of subjects: 130000
Study 15173148 — intervention group
Group type: COMPARATOR
Intervention: Former intervention households
Number of subjects: 130000
Study 11317090 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise classes
Number of subjects: 249
Study 8986678 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidized regenerated cellulose plus heparin (1,000 U/mL)
Number of subjects: 40
Study 8986678 — intervention group
Group type: COMPARATOR
Intervention: Oxidized regenerated cellulose alone
Number of subjects: 40
Study 8490772 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular dexamethasone injection along with oral placebo treatment (Group B)
Number of subjects: 52
Study 8490772 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dexamethasone by a tapering schedule associated with placebo intramuscular injection (Group C)
Number of subjects: 52
Study 8490772 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular and oral placebos (Group A)
Number of subjects: 52
Study 8490772 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular dexamethasone injection (Group B)
Number of subjects: 52
Study 8490772 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dexamethasone by a tapering schedule (Group C)
Number of subjects: 52
Study 3814462 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 60 mg p.o.
Number of subjects: 11
Study 3814462 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 30 mg s.l.
Number of subjects: 11
Study 3814462 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched subjects)
Number of subjects: 11
Study 3814462 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (both doses)
Number of subjects: 11
Study 31177482 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Counseling (CBC)
Number of subjects: 193
Study 31177482 — intervention group
Group type: EXPERIMENTAL
Intervention: Debriefing
Number of subjects: 193
Study 31177482 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 193
Study 28598701 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive exercises (SBT)
Number of subjects: 18
Study 28598701 — intervention group
Group type: COMPARATOR
Intervention: Tetris (active placebo)
Number of subjects: 18
Study 25963350 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic leuprorelin acetate
Number of subjects: 236
Study 25963350 — intervention group
Group type: COMPARATOR
Intervention: Imported leuprorelin acetate
Number of subjects: 236
Study 23523158 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA) in addition to medical therapy
Number of subjects: 15
Study 23523158 — intervention group
Group type: COMPARATOR
Intervention: Delayed PTA after 6 months of medical therapy alone
Number of subjects: 15
Study 21439044 — intervention group
Group type: EXPERIMENTAL
Intervention: BeWEL lifestyle programme (diet, physical activity and behaviour change)
Number of subjects: 452
Study 21439044 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 452
Study 20109997 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride 15 mg TID (up to 90 mg/d if needed)
Number of subjects: 1658
Study 20109997 — intervention group
Group type: COMPARATOR
Intervention: Oxybutynin hydrochloride 2.5 mg TID (up to 15 mg/d if needed)
Number of subjects: 1658
Study 20109997 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride
Number of subjects: 1658
Study 20109997 — intervention group
Group type: COMPARATOR
Intervention: Oxybutynin hydrochloride
Number of subjects: 1658
Study 16424716 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel repeated pulse treatment with methylprednisolone (1 g/day for 3 days) and cyclophosphamide (15 mg/kg/day for 2 days), followed by dexamethasone 20 mg/day until Pao2 was >11.5 kPa, and repeated pulse therapy if Pao2 was <8.64 kPa
Number of subjects: 23
Study 16424716 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 23
Study 15241610 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 21
Study 15241610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 11835041 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumen-centered gamma or beta radiation source
Number of subjects: 28
Study 11835041 — intervention group
Group type: COMPARATOR
Intervention: Noncentered source position
Number of subjects: 28
Study 9578184 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg)
Number of subjects: 14
Study 9578184 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg)
Number of subjects: 14
Study 9578184 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole (40 mg)
Number of subjects: 14
Study 9578184 — intervention group
Group type: EXPERIMENTAL
Intervention: All three proton pump inhibitors
Number of subjects: 14
Study 7865644 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose aspirin (75 mg, 300 mg, enteric coated 300 mg)
Number of subjects: 12
Study 7865644 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain aspirin 75 mg
Number of subjects: 12
Study 7865644 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain aspirin 300 mg
Number of subjects: 12
Study 7865644 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric coated aspirin 300 mg
Number of subjects: 12
Study 7865644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2475678 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic verapamil treatment
Number of subjects: 444
Study 2475678 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 444
Study 770079 — intervention group
Group type: EXPERIMENTAL
Intervention: Azapropazone 1200 mg per day before food
Number of subjects: 23
Study 770079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 31899977 — intervention group
Group type: EXPERIMENTAL
Intervention: Perispinal etanercept
Number of subjects: 0
Study 31899977 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study 31864376 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-referral treatment with rectal artesunate
Number of subjects: 387
Study 28103444 — intervention group
Group type: EXPERIMENTAL
Intervention: simoctocog alfa (Nuwiq)
Number of subjects: 0
Study 25727114 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care intervention for anxiety disorders
Number of subjects: 1004
Study 25727114 — intervention group
Group type: COMPARATOR
Intervention: Usual care for anxiety disorders
Number of subjects: 1004
Study 23548832 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) plus Virtual Reality Exposure Therapy (VRET)
Number of subjects: 55
Study 23548832 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) plus Exposure in Vivo
Number of subjects: 55
Study 23548832 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 55
Study 21741331 — intervention group
Group type: EXPERIMENTAL
Intervention: 4g/L of ascites removed (group 1)
Number of subjects: 70
Study 21741331 — intervention group
Group type: COMPARATOR
Intervention: 8g/L of ascites removed (group 2)
Number of subjects: 70
Study 19201586 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium citrate 300 mg/day for 5 weeks (group 1)
Number of subjects: 32
Study 19201586 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 2)
Number of subjects: 32